Ellen Scherl
Overview
Explore the profile of Ellen Scherl including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
52
Citations
1757
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Lewin S, Long M, Cohen R, Scherl E, Wolf D, Mahadevan U
Inflamm Bowel Dis
. 2025 Jan;
PMID: 39779464
Background: Women with inflammatory bowel disease (IBD) face complexities of disease management during pregnancy and childbirth. Apprehension regarding vaginal delivery in pregnant individuals with IBD persists due to concern for...
2.
Wong R, Charilaou P, Hemperly A, Qin L, Pan Y, Mathani P, et al.
Crohns Colitis 360
. 2024 Dec;
6(4):otae052.
PMID: 39679163
Background: No models predict future outcomes in inflammatory bowel disease (IBD) patients receiving maintenance infliximab therapy. We created a predictive model for unfavorable outcomes. Methods: Adult patients with IBD receiving...
3.
Itzkowitz S, Jiang Y, Villagra C, Colombel J, Sultan K, Lukin D, et al.
Clin Gastroenterol Hepatol
. 2024 May;
PMID: 38768673
Background & Aims: In patients with inflammatory bowel disease (IBD) and a history of cancer, retrospective studies have suggested that exposure to immunosuppressive agents does not increase the risk of...
4.
Wong R, Qin L, Pan Y, Mahtani P, Longman R, Lukin D, et al.
J Clin Med
. 2023 Nov;
12(21).
PMID: 37959261
(1) Many patients with inflammatory bowel disease (IBD) in endoscopic remission have persistent histologic activity, which is associated with worse outcomes. There are limited data on the association between adalimumab...
5.
Smith E, Chen J, Pan Y, Mahtani P, Lukin D, Ahmed W, et al.
J Clin Gastroenterol
. 2023 Aug;
58(6):607-613.
PMID: 37646564
Introduction: The serum-based endoscopic healing index (EHI) test identifies endoscopic Crohn's disease (CD) activity. Data are lacking on the relationship between EHI with other endpoints. We assessed the relationship between...
6.
Rajan A, Pan Y, Mahtani P, Niec R, Longman R, Gerber J, et al.
Crohns Colitis 360
. 2023 Apr;
5(2):otad017.
PMID: 37016720
Background: Discordances between clinical and endoscopic Crohn's disease (CD) activity indices negatively impact the utility of clinic visits and efficacy assessments in clinical trials. Bile acid diarrhea (BAD) and small...
7.
Abraham B, Ott E, Busse C, Murphy C, Miller L, Baumgart D, et al.
Crohns Colitis 360
. 2023 Feb;
4(3):otac025.
PMID: 36777422
Background: While no adverse developmental outcomes were observed in preclinical animal studies, limited data exist regarding effects of ustekinumab on human pregnancies. Previously, no data have been reported for women...
8.
Chen K, Chen J, Smith E, Mathani P, Longman R, Lukin D, et al.
Inflamm Bowel Dis
. 2022 Nov;
29(9):1499-1503.
PMID: 36421052
No abstract available.
9.
Hembree A, Scherl E
Dis Colon Rectum
. 2022 Nov;
65(S1):S85-S91.
PMID: 36399769
Background: In patients with ulcerative colitis or familial adenomatous polyposis who develop neoplasia or fail medical therapy and require colectomy, restorative proctocolectomy with IPAA is often indicated. Although often well...
10.
Sands B, Irving P, Hoops T, Izanec J, Gao L, Gasink C, et al.
Lancet
. 2022 Jun;
399(10342):2200-2211.
PMID: 35691323
Background: Active-comparator trials are important to inform patient and physician choice. We aimed to evaluate the efficacy and safety of monotherapy with either ustekinumab or adalimumab in biologic-naive patients with...